Michael Hofman presents additional data, including patient-reported outcomes, from the phase 2 TheraP study of lutetium-177-prostate-specific membrane antigen-617 in men with metastatic castration-resistant prostate cancer (3:16).
11-02-2021 | ASCO GU 2021 | Conference coverage | Video